Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

P.L. as you know from the years, I have great regard for your thoughts and I assume that my biz/ investment thoughts are of value also.
When the company decides to issue two update calls/ releases it has to weigh other realities.. such as.. what is the frequency of other like kind biotechs?
IMO, at this low S/P, with this stance, it might prove difficult to hold retail investors and to attract new ones. This might portend a weak share price especially in light of near term additional capital needs and dilution.
I understand the company decision making, but have concerns....
Thanks for the healthy dialogue.